2026-05-06T17:24:41-07:00 2025-12-31 990 2025-01-01 473425850 CANCER PREVENTION INITIATIVE INC CANC 8444374891 1722 Routh Street Suite 770 Dallas TX 75201 Theodora Ross President 8444374891 2026-05-06 2025 2025-03-06 01:10:19Z Theodora Ross 1722 Routh Street Suite 770 Dallas TX 75201 778663 0 X www.cancerpreventioninitiative.org X 2015 DE Cancer Prevention Initiative, Inc. (CPI) is a nonprofit corporation whose mission is to accelerate the discovery and development of new medicines that prevent cancer. We support research on prevention of inherited cancers as a path toward the elimination of all cancers. 6 6 0 5 0 0 1604577 701483 0 0 69104 77180 0 0 1673681 778663 650000 725000 0 0 0 0 30000 90000 96789 23827 41539 703827 856539 969854 -77876 2225249 1927394 580179 360200 1645070 1567194 Cancer Prevention Initiative, Inc. (CPI) is a nonprofit corporation whose mission is to accelerate the discovery and development of new medicines that prevent cancer. CPI uses its research, medical and pharmaceutical expertise to invest in first-rate science that will discover new medical methods for preventing cancer. Our strategy is to support research on prevention of inherited cancers as a path towards elimination of all cancers. CPI acts as a facilitator to ensure that good ideas can find sufficient funding to turn them into therapeutic solutions such as drugs or vaccines to prevent cancer. CPI provides financial support, guidance and expertise throughout the research and development process to help researchers use the resources (donations) for the highest possible impact. 0 0 731546 725000 0 In 2025, Cancer Prevention Initiative (CPI) supported five active projects studying therapeutic prevention of inherited cancer. Four of the projects study BRCA1/2 mutated cancers and one project studies Lynch Syndrome. Two of the projects, one at Cleveland Clinic and one at Dana-Farber, are developing immunoprevention strategies to combat BRCA mutant breast cancer. Another immunoprevention project at MD Anderson is developing vaccines to prevent Lynch syndrome-associated colorectal cancer. The project at Harvard/Beth Israel Deaconess Medical center is identifying risk factors in the fallopian tube that gives rise to ovarian cancer in BRCA1 mutation carriers. This work would help develop tests and assays for early detection and risk assessment of ovarian cancer. At Memorial Sloan Kettering Cancer Center, CPI supports a project to prevent Loss of Heterozygosity (LoH) of BRCA genes, a major driver in cancer initiation, and thereby prevent the development of cancer. 0 0 0 Education and engagement programs: As we move closer to our goal of eradicating all cancers through preventative medicines, we believe that raising awareness about inherited cancer syndromes will inspire more individuals to take proactive, life-saving preventive measures. One of the goals is to enhance the scientific reach of the organization and raise awareness on cancer prevention to a broader audience of patients, advocates and donors. Updates on scientific and medical research advances, recent clinical trials, and interviews with experts in cancer prevention are published on web-based platforms. 0 0 0 731546 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 CA CO CT FL IL KS NJ PA X Archer Accountancy Group 8444374891 531 Main Street No 833 El Segundo CA 90245 Theodora Ross President & Chief Scientific Officer; Trustee 5.00 0 X X 0 0 0 Howard Janzen Board Chair; Secretary; Trustee 5 0 X X 0 0 0 Jan Livingston-Mokhtari Trustee 1 0 X 0 0 0 Douglas Hager Trustee, Sr. Vice President, Project Management and Operations 10 0 X 0 0 0 Joi Morris Treasurer, Trustee 6.00 0 X X 0 0 0 Kirk Patrick Secretary, Trustee 0.5 X 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 701483 0 701483 0 77180 0 0 77180 0 0 0 0 0 0 0 0 0 0 0 0 0 0 778663 0 0 77180 725000 725000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12310 0 12310 0 0 0 0 0 90000 90000 0 0 0 0 12250 0 6125 6125 479 0 0 479 2965 0 2780 185 6087 6087 459 459 1600 1600 2832 2832 Dues and Subscriptions 756 0 756 0 Fees and Licenses 1826 0 1826 0 Bank Charges -25 0 -25 0 856539 731546 28204 96789 833 52657 4500 11000 0 0 0 0 0 0 0 0 0 0 0 0 1063 8104 2217253 1855633 1600 0 2225249 1927394 0 10000 580000 350000 0 0 0 0 0 0 179 200 580179 360200 X 328570 535694 1316500 1031500 1645070 1567194 2225249 1927394 -77876 0 0 0 0 0 X 1 X 1 X 1 0 X 135 245219 65 1604578 701483 2551480 135 245219 65 1604578 701483 2551480 2551480 16 11849 49519 69399 77180 207963 0 0 0 0 0 0 2759443 0.92464 0.78347 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 Credit Card Payable 200 200 778663 0 0 0 0 0 778663 0 0 0 778663 856539 0 0 0 0 0 856539 0 0 0 856539 X X 1 Tina Krall DBA MissionCraft Partners 2373 N Chesterfield Ct Charlottesville VA 22911 Fundraising consulting services to assist in managing major gift fundraising efforts, establish and maintain a sustainable donor base, strengthen fundraising infrastructure, and collaborate with the board to enhance donor engagement. 0 71705 90000 -18295 71705 90000 -18295 CA CO CT FL IL KS NJ PA 1 University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 746001118 450000 The purpose of the Grant is for the Principal Investigator to carry out the research to develop immune interventions that could reduce the risk of Lynch Syndrome (LS)-related cancers. The goals of the project are to develop vaccines and test their potential to prevent colorectal cancer in a preclinical model of LS and to explore the colonic immune microenvironment. Memorial Sloan Kettering Cancer Center 1275 York Avenue Box 701 New York NY 10065 131924236 150000 0 This project to identify factors that influence the Loss of Heterozygosity (LOH) was initially funded in 2019. Based on the significant progress made in the project, the project was granted additional funding to continue to phase 2 in 2021 and phase 3 in 2024-2025. During phase 3, they will study allele loss under BRCA wildtype and heterozygous conditions. These studies will provide a comparative mechanistic understanding of LOH at BRCA under normal and carrier conditions. This mechanistic understanding will facilitate development of strategies to prevent LOH and thereby prevent cancer development in high-risk individuals. University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 75390 752556007 125000 Scientific and administrative oversight of all Cancer Prevention Initiative programs. 3 0 Schedule I, Part I, Line 2 CPI conducts independent scientific peer review on all research applications before making grant award decisions. The organization requires regular financial and narrative reports from all grant recipients on the use of grant funds and the research conducted with the funds. Every grant contract contains specific research milestones and deliverables that are tracked throughout the research process. CPI's reporting requirements include reports on all research results and achievement of scheduled milestones. Annual financial reports must provide details regarding monies spent in comparison to the budget. Ongoing research payments are only authorized when satisfactory research reports are received and approved by the scientific team. Form 990, Part VI, Section A, Line 8b Governing body has no committees with authority to act on behalf of the board. Form 990, Part VI, Section B, Line 11b All members of the governing board receive a copy of the 990 prior to filing with the opportunity for input and questions. Form 990, Part VI, Section B, Line 12c The Board of Trustees annually reviews the Conflict of Interest policy and each covered person is annual required to sign a statement that discloses all potential conflicts of interest and affirms that each person: 1. Has received a copy of the Conflict of Interest Policy; 2. Has read and understands the Conflict of Interest Policy; 3. Has agreed to comply with the Conflict of Interest Policy; 4. Understands that CPI is a Charitable organization that in order to maintain its federal tax exemption and the trust of the public, it must diligently avoid conflicts of interest or the appearance of any conflict and engage primarily in activitites that accomplish one or more of its tax-exempt purposes. Form 990, Part VI, Section C, Line 18 CPI complies with IRC Section 6104 in regard to public disclosure. As such, our annual information returns, Conflict of Interest policy, audited financial reports, and governing document are available for public inspection upon request. Form 990, Part VI, Section C, Line 19 CPI complies with IRC Section 6104 in regard to public disclosure. As such, our annual information returns, Conflict of Interest policy, audited financial reports, and governing documents are available for public inspection upon request.